Distinguished in B-Cell Lymphoma

Peter D. Brown

Copenhagen, DK 
Distinguished in B-Cell Lymphoma
Copenhagen, DK 
OverviewLocationsClinical Research

Overview

Peter Brown practices in Copenhagen, Denmark. Mr. Brown is rated as a Distinguished expert by MediFind in the treatment of B-Cell Lymphoma. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 1 clinical trial in the study of B-Cell Lymphoma.

Gender
Male

Locations

Copenhagen, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: June 21, 2024
Intervention Type: Combination product
Study Drugs: R-CHOEP, DA-EPOCH-R
Study Phase: Phase 2
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: Rituximab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

57 Total Publications

Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.
Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.
Journal: European journal of haematology
Published: July 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Brown's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile